Nada Jabado

List of Publications by Year in Descending Order

229 papers	25,277 citations	79 h-index	157 g-index
248 ext. papers	31,039 ext. citations	13.5 avg, IF	5.85 L-index

#	Paper	IF	Citations
229	DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma. *Neuro-Oncology*, **2022**, 24, i21-i21	1	
228	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. *Neuro-Oncology*, **2022**, 24, i61-i62	1	
227	HGG-36. Elucidating the role of long non-coding RNAs in pediatric high grade gliomas. *Neuro-Oncology*, **2022**, 24, i68-i69	1	
226	LGG-26. Predicting MAPK inhibitor sensitivity in pediatric low-grade gliomas with novel gene expression-derived signatures. *Neuro-Oncology*, **2022**, 24, i93-i94	1	
225	LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology. *Neuro-Oncology*, **2022**, 24, i101-i102	1	
224	DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers. *Neuro-Oncology*, **2022**, 24, i21-i22	1	
223	Histone H3.3 K27M and K36M mutations de-repress transposable elements through perturbation of antagonistic chromatin marks. *Molecular Cell*, **2021**, 81, 4876-4890.e7	17.6	5
222	Management of Inoperable Supra-Sellar Low-Grade Glioma With BRAF Mutation in Young Children.. *Cureus*, **2021**, 13, e19400	1.2	
221	CTNI-06. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. *Neuro-Oncology*, **2021**, 23, vi59-vi60	1	
220	Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas. *Science Translational Medicine*, **2021**, 13, eabf7860	17.5	2
219	ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. *Cancer Discovery*, **2021**, 11, 2200-2215	24.4	16
218	The transcriptional landscape of Shh medulloblastoma. *Nature Communications*, **2021**, 12, 1749	17.4	7
217	Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. *Blood Advances*, **2021**, 5, 1682-1694	7.8	13
216	Oncohistones: a roadmap to stalled development. *FEBS Journal*, **2021**,	5.7	3
215	Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors. *Acta Neuropathologica*, **2021**, 142, 361-374	14.3	2
214	Whole-exome sequencing reveals novel vacuolar ATPase genesRvariants and variants in genes involved in lysosomal biology and autophagosomal formation in oral granular cell tumors. *Journal of Oral Pathology and Medicine*, **2021**, 50, 410-417	3.3	3
213	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. *Neuro-Oncology*, **2021**, 23, 34-43	1	22

212	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients. *Current Oncology*, **2021**, 28, 346-366	2.8	9
211	Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas. *Nature Communications*, **2021**, 12, 971	17.4	17
210	De novo Leu619Pro variant causes a new channelopathy characterised by giant cell lesions of the jaws and skull, skeletal abnormalities and polyneuropathy. *Journal of Medical Genetics*, **2021**,	5.8	1
209	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. *Journal of Clinical Oncology*, **2021**, 39, 807-821	2.2	7
208	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. *Acta Neuropathologica*, **2021**, 142, 827-839	14.3	5
207	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. *The Lancet Child and Adolescent Health*, **2021**, 5, 800-813	14.5	1
206	Polycomb repressive complex 2 in the driver's seat of childhood and young adult brain tumours. *Trends in Cell Biology*, **2021**, 31, 814-828	18.3	5
205	EPCO-06. AGE- AND REGION-SPECIFIC MULTI-OMIC CHARACTERIZATION OF H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA. *Neuro-Oncology*, **2021**, 23, vi2-vi2	1	
204	An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data. *Acta Neuropathologica*, **2020**, 140, 237-239	14.3	3
203	Incidence trends in pediatric central nervous system tumors in Canada: a 15 years report from Cancer and Young People in Canada (CYP-C) registry. *Neuro-Oncology Advances*, **2020**, 2, vdaa012	0.9	2
202	ETMR-17. SINGLE-CELL TRANSCRIPTOME ANALYSIS OF ETMR PATIENT SAMPLES. *Neuro-Oncology*, **2020**, 22, iii326-iii326	1	78
201	LGG-35. FUNCTIONAL GENOMIC APPROACHES TO IDENTIFY THERAPEUTIC TARGETS IN MYB AND MYBL1 EXPRESSING PEDIATRIC LOW-GRADE GLIOMAS. *Neuro-Oncology*, **2020**, 22, iii373-iii373	1	78
200	LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. *Neuro-Oncology*, **2020**, 22, iii371-iii371	1	1
199	Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. *Cell*, **2020**, 181, 1329-1345.e24	36.4	40
198	YAP1-fusions in pediatric NF2-wildtype meningioma. *Acta Neuropathologica*, **2020**, 139, 215-218	14.3	24
197	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. *Acta Neuropathologica*, **2020**, 139, 223-241	14.3	28
196	Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. *Neuropathology and Applied Neurobiology*, **2020**, 46, 422-430	5.2	15
195	Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 27354-27364	11.5	26

194	Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. *Cell Reports*, **2020**, 33, 108286	10.6	10
193	Entering the era of precision medicine in pediatric oncology. *Nature Medicine*, **2020**, 26, 1684-1685	50.5	4
192	H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2. *Molecular Cell*, **2020**, 80, 726-735.e7	17.6	32
191	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. *European Journal of Cancer*, **2020**, 139, 135-148	7.5	12
190	Epigenomic programming in early fetal brain development. *Epigenomics*, **2020**, 12, 1053-1070	4.4	2
189	Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). *Journal of Neuro-Oncology*, **2020**, 149, 45-54	4.8	4
188	H3K27M in Gliomas Causes a One-Step Decrease in H3K27 Methylation and Reduced Spreading within the Constraints of H3K36 Methylation. *Cell Reports*, **2020**, 33, 108390	10.6	14
187	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. *Cell*, **2020**, 183, 1617-1633.e22	56.2	29
186	H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone. *Cancer Discovery*, **2020**, 10, 1968-1987	24.4	14
185	Canadian Pediatric Neuro-Oncology Standards of Practice. *Frontiers in Oncology*, **2020**, 10, 593192	5.3	2
184	Successful treatment of non-midline primary malignant germ cell tumors with yolk sac components in neonates: report of 2 cases. *Journal of Neurosurgery: Pediatrics*, **2020**, 1-5	2.1	
183	The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape. *Nature*, **2019**, 573, 281-286	50.4	161
182	Recurrent inflammatory disease caused by a heterozygous mutation in CD48. *Journal of Allergy and Clinical Immunology*, **2019**, 144, 1441-1445.e17	11.5	5
181	Identification of genes functionally involved in the detrimental effects of mutant histone H3.3-K27M in Drosophila melanogaster. *Neuro-Oncology*, **2019**, 21, 628-639	1	3
180	PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. *Nature Communications*, **2019**, 10, 2146	17.4	76
179	Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. *Cancer Cell*, **2019**, 35, 782-797.e8	24.3	52
178	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. *Nature*, **2019**, 572, 67-73	50.4	149
177	Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers. *JAMA Network Open*, **2019**, 2, e192906	10.4	18

176	H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis. *Nature Communications*, **2019**, 10, 1262	17.4	104
175	DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. *Clinical Epigenetics*, **2019**, 11, 117	7.7	12
174	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. *Cancer Cell*, **2019**, 36, 51-67.e7	24.3	39
173	Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness. *Nature Communications*, **2019**, 10, 2891	17.4	23
172	Single Cell Transcriptomic Analysis of the Histone H3 K27M Mutation in Pre-Leukemic Hematopoietic Stem Cells. *Blood*, **2019**, 134, 3773-3773	2.2	
171	Stalled developmental programs at the root of pediatric brain tumors. *Nature Genetics*, **2019**, 51, 1702-1713	30.3	58
170	The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas. *Annual Review of Genetics*, **2019**, 53, 483-503	14.5	14
169	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. *BMC Cancer*, **2019**, 19, 1250	4.8	42
168	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. *Nature*, **2019**, 574, 707-711	50.4	78
167	The molecular landscape of ETMR at diagnosis and relapse. *Nature*, **2019**, 576, 274-280	50.4	46
166	Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma. *Oncogene*, **2019**, 38, 2994-3002	9.2	11
165	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. *Cell*, **2018**, 172, 1050-1062.e14	36.2	46
164	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. *Clinical Cancer Research*, **2018**, 24, 1355-1363	12.9	15
163	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. *Nature*, **2018**, 553, 101-105	50.4	116
162	DNA methylation-based classification of central nervous system tumours. *Nature*, **2018**, 555, 469-474	50.4	992
161	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. *Lancet Oncology, The*, **2018**, 19, 785-798	21.7	159
160	Methylome analysis and whole-exome sequencing reveal that brain tumors associated with encephalocraniocutaneous lipomatosis are midline pilocytic astrocytomas. *Acta Neuropathologica*, **2018**, 136, 657-660	14.3	12
159	Trametinib for progressive pediatric low-grade gliomas. *Journal of Neuro-Oncology*, **2018**, 140, 435-444	4.8	52

158	Pediatric low-grade gliomas: next biologically driven steps. *Neuro-Oncology*, **2018**, 20, 160-173	1	76
157	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. *Journal of Clinical Oncology*, **2018**, 36, 1963-1972	2.2	125
156	Reduced recruitment of 53BP1 during interstrand crosslink repair is associated with genetically inherited attenuation of mitomycin C sensitivity in a family with Fanconi anemia. *Oncotarget*, **2018**, 9, 3779-3793	3.3	2
155	PDTM-21. MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA. *Neuro-Oncology*, **2018**, 20, vi208-vi208	1	1
154	TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw. *Nature Communications*, **2018**, 9, 4572	17.4	30
153	Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. *Nature Genetics*, **2018**, 50, 1650-1657	36.3	74
152	Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. *Pediatric Blood and Cancer*, **2018**, 65, e27389	3	17
151	Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. *Journal of Neuro-Oncology*, **2017**, 132, 155-162	4.8	29
150	Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas. *Nature Genetics*, **2017**, 49, 180-185	36.3	132
149	Spatial heterogeneity in medulloblastoma. *Nature Genetics*, **2017**, 49, 780-788	36.3	80
148	Intertumoral Heterogeneity within Medulloblastoma Subgroups. *Cancer Cell*, **2017**, 31, 737-754.e6	24.3	511
147	Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?. *Neuro-Oncology*, **2017**, 19, 1025-1034	1	58
146	H3.3 Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. *Cancer Cell*, **2017**, 32, 684-700.e9	24.3	121
145	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. *Cancer Cell*, **2017**, 32, 520-537.e5	24.3	423
144	Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. *Acta Neuropathologica Communications*, **2017**, 5, 78	7.3	23
143	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. *Journal of Clinical Oncology*, **2017**, 35, 2934-2941	2.2	153
142	Pediatric high-grade glioma: biologically and clinically in need of new thinking. *Neuro-Oncology*, **2017**, 19, 153-161	1	125
141	The whole-genome landscape of medulloblastoma subtypes. *Nature*, **2017**, 547, 311-317	50.4	472

140	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. *Acta Neuropathologica*, **2017**, 134, 705-714	14.3	114
139	H3.1 K36M mutation in a congenital-onset soft tissue neoplasm. *Pediatric Blood and Cancer*, **2017**, 64, e26633	3	3
138	Brainstem angiocentric gliomas with MYB-QKI rearrangements. *Acta Neuropathologica*, **2017**, 134, 667-669	14.3	11
137	Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma. *Pediatric Blood and Cancer*, **2017**, 64, 275-278	3	4
136	Pediatric low-grade gliomas: implications of the biologic era. *Neuro-Oncology*, **2017**, 19, 750-761	1	47
135	X-linked primary immunodeficiency associated with hemizygous mutations in the moesin (MSN) gene. *Journal of Allergy and Clinical Immunology*, **2016**, 138, 1681-1689.e8	11.5	45
134	Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. *Journal of Clinical Oncology*, **2016**, 34, 3537-3543	2.2	105
133	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. *Nature Communications*, **2016**, 7, 11185	17.4	152
132	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. *Journal of Clinical Oncology*, **2016**, 34, 2468-77	2.2	113
131	Divergent clonal selection dominates medulloblastoma at recurrence. *Nature*, **2016**, 529, 351-7	50.4	206
130	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. *Journal of Clinical Oncology*, **2016**, 34, 2206-11	2.2	537
129	Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment. *American Journal of Pathology*, **2016**, 186, 446-59	5.8	28
128	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. *Nature Genetics*, **2016**, 48, 273-82	36.3	154
127	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. *Cancer Cell*, **2016**, 29, 379-393	24.3	319
126	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. *Cell*, **2016**, 164, 1060-1072	36.2	483
125	Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. *Acta Neuropathologica*, **2016**, 131, 847-63	14.3	105
124	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. *Lancet Oncology, The*, **2016**, 17, 484-495	21.7	187
123	Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care. *Clinical Genetics*, **2016**, 89, 275-84	4	243

122	Barriers to horizontal cell transformation by extracellular vesicles containing oncogenic H-ras. *Oncotarget*, **2016**, 7, 51991-52002	3.3	57
121	Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor. *Oncotarget*, **2016**, 7, 1732-40	3.3	36
120	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. *Cancer Cell*, **2016**, 30, 891-908	24.3	135
119	Murine diet/tissue and human brain tumorigenesis alter Mthfr/MTHFR 5Rend methylation. *Mammalian Genome*, **2016**, 27, 122-34	3.2	4
118	Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. *Science*, **2016**, 352, 844-9	33.3	219
117	White matter and information processing speed following treatment with cranial-spinal radiation for pediatric brain tumor. *Neuropsychology*, **2016**, 30, 425-38	3.8	33
116	Changes in the expression profiles of claudins during gonocyte differentiation and in seminomas. *Andrology*, **2016**, 4, 95-110	4.2	10
115	Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. *Clinical Cancer Research*, **2015**, 21, 184-92	12.9	63
114	Preclinical target validation using patient-derived cells. *Nature Reviews Drug Discovery*, **2015**, 14, 149-50	64.1	40
113	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. *Acta Neuropathologica*, **2015**, 129, 669-78	14.3	220
112	The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience. *Childs Nervous System*, **2015**, 31, 57-65	1.7	15
111	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. *Lancet Oncology, The*, **2015**, 16, 569-82	21.7	117
110	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. *Clinical Cancer Research*, **2015**, 21, 3750-8	12.9	35
109	MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. *Cancer Cell*, **2015**, 28, 715-729	24.3	64
108	An inherited immunoglobulin class-switch recombination deficiency associated with a defect in the INO80 chromatin remodeling complex. *Journal of Allergy and Clinical Immunology*, **2015**, 135, 998-1007.e6	11.5	30
107	Promoting an ethic of engagement in pediatric palliative care research. *BMC Palliative Care*, **2015**, 14, 50	3	12
106	Pachyonychia Congenita (K16) with Unusual Features and Good Response to Acitretin. *Case Reports in Dermatology*, **2015**, 7, 220-6	1.1	7
105	EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study. *Cancer*, **2015**, 121, 1499-507	6.4	27

104	Pediatric Brain Tumors: Genomics and Epigenomics Pave the Way. *Critical Reviews in Oncogenesis*, **2015**, 20, 271-99	1.3	5
103	Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age. *Oncotarget*, **2015**, 6, 31844-56	3.3	10
102	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. *Nature*, **2014**, 506, 445-50	50.4	434
101	Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell*, **2014**, 25, 393-405	24.3	469
100	CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. *Nature*, **2014**, 510, 288-92	50.4	131
99	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. *Nature Reviews Cancer*, **2014**, 14, 92-107	31.3	383
98	Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. *Nature Genetics*, **2014**, 46, 39-44	36.3	131
97	Cytogenetic prognostication within medulloblastoma subgroups. *Journal of Clinical Oncology*, **2014**, 32, 886-96	2.2	199
96	Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 3544-9	11.5	78
95	Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. *Acta Neuropathologica*, **2014**, 128, 853-62	14.3	38
94	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. *Acta Neuropathologica*, **2014**, 128, 733-41	14.3	96
93	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. *Nature Genetics*, **2014**, 46, 462-6	36.3	296
92	Attitudes of parents toward the return of targeted and incidental genomic research findings in children. *Genetics in Medicine*, **2014**, 16, 633-40	8.1	67
91	Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. *Acta Neuropathologica*, **2014**, 128, 615-27	14.3	29
90	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nature Genetics*, **2013**, 45, 927-32	36.3	550
89	Phosphoinositide 3-kinase gene mutation predisposes to respiratory infection and airway damage. *Science*, **2013**, 342, 866-71	33.3	424
88	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. *Lancet Oncology, The*, **2013**, 14, 1200-7	21.7	226
87	Whole-exome sequencing identifies Coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation. *Journal of Allergy and Clinical Immunology*, **2013**, 131, 1594-603	11.5	111

86	Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. *Cancer Cell*, **2013**, 24, 660-72	24.3	478
85	Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. *Genome Medicine*, **2013**, 5, 66	14.4	17
84	A recurrent PDGFRB mutation causes familial infantile myofibromatosis. *American Journal of Human Genetics*, **2013**, 92, 996-1000	11	108
83	Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. *Brain Pathology*, **2013**, 23, 210-6	6	64
82	Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours. *Proteomics*, **2013**, 13, 1595-607	4.8	22
81	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. *Acta Neuropathologica*, **2013**, 125, 659-69	14.3	201
80	Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. *Acta Neuropathologica*, **2013**, 126, 291-301	14.3	70
79	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. *Acta Neuropathologica*, **2013**, 126, 917-29	14.3	115
78	Iron refractory iron deficiency anemia: presentation with hyperferritinemia and response to oral iron therapy. *Pediatrics*, **2013**, 131, e620-5	7.4	15
77	Molecular biomarkers in pediatric glial tumors: a needed wind of change. *Current Opinion in Oncology*, **2013**, 25, 665-73	4.2	11
76	A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. *Neuro-Oncology*, **2013**, 15, 462-8	1	93
75	Human RTEL1 deficiency causes Hoyeraal-Hreidarsson syndrome with short telomeres and genome instability. *Human Molecular Genetics*, **2013**, 22, 3239-49	5.6	113
74	Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. *Journal of Clinical Oncology*, **2013**, 31, 2927-35	2.2	290
73	Attitudes of Canadian researchers toward the return to participants of incidental and targeted genomic findings obtained in a pediatric research setting. *Genetics in Medicine*, **2013**, 15, 558-64	8.1	41
72	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. *Acta Neuropathologica*, **2012**, 124, 615-25	14.3	295
71	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. *Acta Neuropathologica*, **2012**, 124, 439-47	14.3	629
70	Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell*, **2012**, 22, 425-37	24.3	1243
69	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. *Cell*, **2012**, 148, 59-71	56.2	600

68	Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. *European Journal of Cancer*, **2012**, 48, 353-9	7.5	146
67	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature*, **2012**, 482, 226-31	50.4	1655
66	Clonal selection drives genetic divergence of metastatic medulloblastoma. *Nature*, **2012**, 482, 529-33	50.4	322
65	Dissecting the genomic complexity underlying medulloblastoma. *Nature*, **2012**, 488, 100-5	50.4	623
64	Acquired Omenn-like syndrome, a novel posttransplant autoaggression syndrome reversed by rapamycin. *Vaccine Journal*, **2012**, 19, 109-12		1
63	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature*, **2012**, 488, 49-56	50.4	596
62	Attitudes of Researchers to the Return of Incidental and Targeted Genomic Findings Obtained in a Research Setting to Participants. *Blood*, **2012**, 120, 2069-2069	2.2	
61	What can exome sequencing do for you?. *Journal of Medical Genetics*, **2011**, 48, 580-9	5.8	263
60	Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma. *Acta Neuropathologica*, **2011**, 121, 229-39	14.3	34
59	Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. *Acta Neuropathologica*, **2011**, 121, 763-74	14.3	176
58	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. *Acta Neuropathologica*, **2011**, 122, 231-40	14.3	159
57	BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. *Clinical Cancer Research*, **2011**, 17, 4790-8	12.9	178
56	Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. *Clinical Cancer Research*, **2011**, 17, 4650-60	12.9	103
55	Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. *Neuro-Oncology*, **2010**, 12, 153-63	1	60
54	Biomarkers in cancer micrometastasis: where are we at?. *Bioanalysis*, **2010**, 2, 881-99	2.1	9
53	Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. *Cancer Research*, **2010**, 70, 2548-57	10.1	127
52	New technologies for the detection of circulating tumour cells. *British Medical Bulletin*, **2010**, 94, 49-64	5.4	89
51	Unexpected allelic heterogeneity and spectrum of mutations in Fowler syndrome revealed by next-generation exome sequencing. *Human Mutation*, **2010**, 31, 918-23	4.7	100

50	FOXP3 forkhead domain mutation and regulatory T cells in the IPEX syndrome. *New England Journal of Medicine*, **2009**, 361, 1710-3	59.2	91
49	Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. *Molecular Cancer Therapeutics*, **2009**, 8, 3276-84	6.1	46
48	PAX3 is expressed in the stromal compartment of the developing kidney and in Wilms tumors with myogenic phenotype. *Pediatric and Developmental Pathology*, **2009**, 12, 347-54	2.2	6
47	Intestinal neoplasia induced by low dietary folate is associated with altered tumor expression profiles and decreased apoptosis in mouse normal intestine. *Journal of Nutrition*, **2009**, 139, 488-94	4.1	15
46	Relative CD4 lymphopenia and a skewed memory phenotype are the main immunologic abnormalities in a child with Omenn syndrome due to homozygous RAG1-C2633T hypomorphic mutation. *Clinical Immunology*, **2009**, 131, 447-55	9	7
45	Wilms tumor arising in a child with X-linked nephrogenic diabetes insipidus. *Pediatric Nephrology*, **2009**, 24, 1313-9	3.2	2
44	Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine. *Childs Nervous System*, **2009**, 25, 39-45	1.7	16
43	Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. *British Journal of Cancer*, **2009**, 101, 722-33	8.7	141
42	Circulating tumor cells: detection, molecular profiling and future prospects. *Expert Review of Proteomics*, **2007**, 4, 741-56	4.2	80
41	Reduced in vitro functional activity of human NRAMP1 (SLC11A1) allele that predisposes to increased risk of pediatric tuberculosis disease. *Genes and Immunity*, **2007**, 8, 691-8	4.4	17
40	Long-term therapy with aerosolized ribavirin for parainfluenza 3 virus respiratory tract infection in an infant with severe combined immunodeficiency. *Pediatric Transplantation*, **2007**, 11, 209-13	1.8	26
39	Gene expression profiling from formalin-fixed paraffin-embedded tumors of pediatric glioblastoma. *Clinical Cancer Research*, **2007**, 13, 6284-92	12.9	55
38	Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. *Journal of Clinical Oncology*, **2007**, 25, 1196-208	2.2	172
37	Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease. *Pediatrics*, **2006**, 118, e537-9	7.4	7
36	Isolation of a natural inhibitor of human malignant glial cell invasion: inter alpha-trypsin inhibitor heavy chain 2. *Cancer Research*, **2006**, 66, 1464-72	10.1	28
35	Atypical presentation of acute promyelocytic leukaemia. *British Journal of Haematology*, **2006**, 132, 379-80	4.5	5
34	Inhibition of medulloblastoma cell invasion by Slit. *Oncogene*, **2006**, 25, 5103-12	9.2	62
33	Fibrinogen Montreal: a novel missense mutation (Aa D496N) associated with hypofibrinogenaemia. *Thrombosis and Haemostasis*, **2006**, 96, 231-2	7	3

32	Pediatric hemophagocytic syndromes: a diagnostic and therapeutic challenge. *Allergy, Asthma and Clinical Immunology*, **2005**, 1, 142-60	3.2	4
31	Complete DiGeorge anomaly in the absence of neonatal hypocalcemia and velofacial and cardiac defects. *Pediatrics*, **2005**, 116, e457-60	7.4	8
30	Impact of HLA matching on outcome of hematopoietic stem cell transplantation in children with inherited diseases: a single-center comparative analysis of genoidentical, haploidentical or unrelated donors. *Bone Marrow Transplantation*, **2004**, 33, 1089-95	4.4	36
29	Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3. *Journal of Clinical Investigation*, **2004**, 114, 1512-7	15.9	52
28	Iron chelators modulate the fusogenic properties of Salmonella-containing phagosomes. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 6127-32	11.5	42
27	Nramp1 modifies the fusion of Salmonella typhimurium-containing vacuoles with cellular endomembranes in macrophages. *Journal of Biological Chemistry*, **2002**, 277, 2258-65	5.4	68
26	Iron transporter Nramp2/DMT-1 is associated with the membrane of phagosomes in macrophages and Sertoli cells. *Blood*, **2002**, 100, 2617-22	2.2	56
25	Lymphoproliferative disorders in children with primary immunodeficiencies: immunological status may be more predictive of the outcome than other criteria. *Histopathology*, **2001**, 38, 146-59	7.3	33
24	Nramp 2 (DCT1/DMT1) expressed at the plasma membrane transports iron and other divalent cations into a calcein-accessible cytoplasmic pool. *Journal of Biological Chemistry*, **2000**, 275, 35738-45	5.4	152
23	A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. *Human Molecular Genetics*, **2000**, 9, 583-8	5.6	79
22	Natural resistance to intracellular infections: natural resistance-associated macrophage protein 1 (Nramp1) functions as a pH-dependent manganese transporter at the phagosomal membrane. *Journal of Experimental Medicine*, **2000**, 192, 1237-48	16.6	322
21	Protein truncation test of LYST reveals heterogenous mutations in patients with Chediak-Higashi syndrome. *Blood*, **2000**, 95, 979-83	2.2	65
20	Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity. *American Journal of Human Genetics*, **1999**, 64, 172-9	11	126
19	Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. *Journal of Pediatrics*, **1999**, 134, 589-96	3.6	245
18	Ligands of CD4 inhibit the association of phospholipase Cgamma1 with phosphoinositide 3 kinase in T cells: regulation of this association by the phosphoinositide 3 kinase activity. *European Journal of Immunology*, **1998**, 28, 3183-91	6.1	18
17	Stem cell transplantation for immunodeficiency. *Seminars in Immunopathology*, **1998**, 19, 479-92		10
16	Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation. *British Journal of Haematology*, **1998**, 103, 543-51	4.5	46
15	The protein tyrosine kinase p60c-Src is not implicated in the pathogenesis of the human autosomal recessive form of osteopetrosis: a study of 13 children. *Journal of Pediatrics*, **1998**, 133, 537-43	3.6	6

14	Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. *Clinical Infectious Diseases*, **1998**, 27, 1437-41	11.6	120
13	Differential CD4-dependent inhibition of JNK but not Erk-2 activities in human naive and memory CD4+ T cell populations. *International Immunology*, **1998**, 10, 869-76	4.9	5
12	Sam68 association with p120GAP in CD4+ T cells is dependent on CD4 molecule expression. *Journal of Immunology*, **1998**, 161, 2798-803	5.3	26
11	In vivo infusion of anti-LFA-1 and anti-CD2 antibodies prevents graft failure after HLA partially incompatible bone marrow transplantation in children with high risk acute lymphoblastic leukaemia. *Leukemia and Lymphoma*, **1997**, 28, 103-12	1.9	8
10	Treatment of Familial Hemophagocytic Lymphohistiocytosis With Bone Marrow Transplantation From HLA Genetically Nonidentical Donors. *Blood*, **1997**, 90, 4743-4748	2.2	106
9	Frequency and Severity of Central Nervous System Lesions in Hemophagocytic Lymphohistiocytosis. *Blood*, **1997**, 89, 794-800	2.2	197
8	Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. *Nature Genetics*, **1997**, 16, 289-92	36.3	372
7	gp160 of HIV or anti-CD4 monoclonal antibody ligation of CD4 induces inhibition of JNK and ERK-2 activities in human peripheral CD4+ T lymphocytes. *European Journal of Immunology*, **1997**, 27, 397-404	6.1	28
6	Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. *European Journal of Immunology*, **1997**, 27, 2043-7	6.1	42
5	CD4 ligands inhibit the formation of multifunctional transduction complexes involved in T cell activation. *Journal of Immunology*, **1997**, 158, 94-103	5.3	44
4	Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. *Blood*, **1997**, 89, 794-800	2.2	54
3	Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors. *Blood*, **1997**, 90, 4743-8	2.2	21
2	Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection. *Pediatrics*, **1996**, 98, 420-8	7.4	33
1	Interaction of HIV gp120 and anti-CD4 antibodies with the CD4 molecule on human CD4+ T cells inhibits the binding activity of NF-AT, NF-kappa B and AP-1, three nuclear factors regulating interleukin-2 gene enhancer activity. *European Journal of Immunology*, **1994**, 24, 2646-52	6.1	51